NT Pharma postpones circular on loan-capitalisation share subscription to 31 July 2026

Bulletin Express

Jul 10

China NT Pharma Group Company Limited (NT Pharma) has delayed the dispatch of its shareholder circular related to the proposed loan capitalisation and share subscription under a specific mandate.

The circular—covering full details of the subscription agreements, the loan capitalisation terms, the notice of extraordinary general meeting (EGM) and accompanying proxy form—was originally scheduled for release within 15 business days of the company’s 17 June 2026 announcement, with an initial deadline of 10 July 2026. NT Pharma now expects to distribute the document on or before 31 July 2026, citing the need for additional time to prepare and finalise certain information.

The board remains led by Chairman Ng Tit, with executive director Ng Anna Ching Mei, non-executive directors Dr. Qian Wei, Chin Yu and Lou Yongbin, and independent non-executive directors Yu Tze Shan Hailson, Kwok Che Chung and Dr. Zhao Yubiao.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/1156429773"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156429773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156429773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156429773","market":"hk","top_or_hot":-1,"title":"NT Pharma postpones circular on loan-capitalisation share subscription to 31 July 2026","media":"Bulletin Express","content":"<p>China NT Pharma Group Company Limited (NT Pharma) has delayed the dispatch of its shareholder circular related to the proposed loan capitalisation and share subscription under a specific mandate.</p>\n<p>The circular—covering full details of the subscription agreements, the loan capitalisation terms, the notice of extraordinary general meeting (EGM) and accompanying proxy form—was originally scheduled for release within 15 business days of the company’s 17 June 2026 announcement, with an initial deadline of 10 July 2026. NT Pharma now expects to distribute the document on or before 31 July 2026, citing the need for additional time to prepare and finalise certain information.</p>\n<p>The board remains led by Chairman Ng Tit, with executive director Ng Anna Ching Mei, non-executive directors Dr. Qian Wei, Chin Yu and Lou Yongbin, and independent non-executive directors Yu Tze Shan Hailson, Kwok Che Chung and Dr. Zhao Yubiao.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NT Pharma postpones circular on loan-capitalisation share subscription to 31 July 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNT Pharma postpones circular on loan-capitalisation share subscription to 31 July 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-10 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China NT Pharma Group Company Limited (NT Pharma) has delayed the dispatch of its shareholder circular related to the proposed loan capitalisation and share subscription under a specific mandate.</p>\n<p>The circular—covering full details of the subscription agreements, the loan capitalisation terms, the notice of extraordinary general meeting (EGM) and accompanying proxy form—was originally scheduled for release within 15 business days of the company’s 17 June 2026 announcement, with an initial deadline of 10 July 2026. NT Pharma now expects to distribute the document on or before 31 July 2026, citing the need for additional time to prepare and finalise certain information.</p>\n<p>The board remains led by Chairman Ng Tit, with executive director Ng Anna Ching Mei, non-executive directors Dr. Qian Wei, Chin Yu and Lou Yongbin, and independent non-executive directors Yu Tze Shan Hailson, Kwok Che Chung and Dr. Zhao Yubiao.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01011","symbol_name":"泰凌医药","start_time":0,"source_url":"","article_id":"1156429773","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156429773","pubTimestamp":1783672938,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China NT Pharma Group Company Limited (NT Pharma) has delayed the dispatch of its shareholder circular related to the proposed loan capitalisation and share subscription under a specific mandate. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01011":"泰凌医药"},"translate_title":"NT Pharma 将贷款资本化股份认购通函推迟至 2026 年 7 月 31 日","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"China NT Pharma Group Company Limited (NT Pharma) has delayed the dispatch of its shareholder circular related to the proposed loan capitalisation and share subscription under a specific mandate.\nThe circular—covering full details of the subscription agreements, the loan capitalisation terms, the notice of extraordinary general meeting (EGM) and accompanying proxy form—was originally scheduled for release within 15 business days of the company’s 17 June 2026 announcement, with an initial deadline of 10 July 2026. NT Pharma now expects to distribute the document on or before 31 July 2026, citing the need for additional time to prepare and finalise certain information.\nThe board remains led by Chairman Ng Tit, with executive director Ng Anna Ching Mei, non-executive directors Dr. Qian Wei, Chin Yu and Lou Yongbin, and independent non-executive directors Yu Tze Shan Hailson, Kwok Che Chung and Dr. Zhao Yubiao.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}